ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report)'s share price traded up 15.1% on Monday . The company traded as high as $2.46 and last traded at $2.38. 8,870,087 shares changed hands during mid-day trading, an increase of 65% from the average session volume of 5,384,321 shares. The stock had previously closed at $2.07.
Analyst Ratings Changes
A number of brokerages have recently issued reports on IBRX. HC Wainwright restated a "buy" rating and issued a $8.00 price objective on shares of ImmunityBio in a research note on Monday. D. Boral Capital reissued a "buy" rating and set a $30.00 price target on shares of ImmunityBio in a report on Monday. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $12.19.
Get Our Latest Stock Report on ImmunityBio
ImmunityBio Price Performance
The stock's 50 day simple moving average is $2.65 and its two-hundred day simple moving average is $3.34. The stock has a market cap of $2.37 billion, a P/E ratio of -2.92 and a beta of 0.33.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.03). The business had revenue of $16.52 million for the quarter, compared to analysts' expectations of $17.50 million. As a group, analysts forecast that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.
Institutional Trading of ImmunityBio
A number of institutional investors have recently made changes to their positions in the business. Freedom Investment Management Inc. bought a new stake in ImmunityBio during the 1st quarter worth about $41,000. Compound Planning Inc. bought a new position in ImmunityBio in the 1st quarter valued at about $30,000. Humankind Investments LLC bought a new position in ImmunityBio in the 1st quarter valued at about $34,000. Hsbc Holdings PLC raised its holdings in ImmunityBio by 151.8% in the 1st quarter. Hsbc Holdings PLC now owns 42,404 shares of the company's stock valued at $126,000 after acquiring an additional 25,564 shares during the period. Finally, Rathbones Group PLC grew its position in shares of ImmunityBio by 8.1% during the 1st quarter. Rathbones Group PLC now owns 96,620 shares of the company's stock worth $291,000 after purchasing an additional 7,200 shares in the last quarter. Institutional investors own 8.58% of the company's stock.
About ImmunityBio
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Recommended Stories
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
